Nanologix Inc (NNLX) 0.0310 $NNLX
NanoLogix Announces Publication of a Study in Journal of Microbiology and Experimentation
Marketwired - Tue Jan 05, 5:00AM CST
NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce publication in the Journal of Microbiology and Experimentation of a peer-reviewed study demonstrating dramatically extended shelf life and high-temperature durability of filled petri plates packed in NanoLogix-manufactured gas-charged FlatPacks. The study was performed by one of the world's largest and most prestigious Biomedical Research Centers.
NanoLogix Announces Diagnostic Customization for Major Medical Device Company
Marketwired - Mon Dec 21, 5:00AM CST
NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
E.coli Testing Market (Environmental Testing and Clinical Testing) - Trends and Forecast 2014 - 2022
M2 - Fri Jul 31, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgchcs/e_coli_testing) has announced the addition of the "E.coli Testing Market (Environmental Testing and Clinical Testing) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Microbial testing is one of the important parameters considered for potability of water. This research report on the E.coli testing market explains various advancements in this market and analyzes the global E.coli testing market based on testing method, end-user and geographic regions. This report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments that are included in the report in a precise manner. Environmental E.Coli testing methods are further segmented as membrane filtration, multiple tube fermentation and enzyme substrate methods.Membrane filtration is the most widely used method for bacterial enumeration due its accuracy. However, increasing popularity of P/A tests is expected to alter the trend. The market size and forecast in terms of USD million for each tests has been provided for the period from 2014 to 2022, considering 2012 and 2013 as base years. Apart from revenue analysis, the report also provides volume analysis for each of the segments and sub-segments. The global E.coli testing market report also provides compound annual growth rate (CAGR) for each of the market segment and sub-segment for the forecast period from 2014 to 2022. Companies Mentioned - Abbott Laboratories - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - CPI International, Inc. - Danaher Corporation - EMLab P&K, LLC - Ecolab, Inc. - F.Hoffmann-La Roche Ltd. - IDEXX Laboratories, Inc. - Meridian Bioscience, Inc. - Micrology Laboratories - NanoLogix, Inc. - Nelson Analytical Lab - Pro Lab Diagnostics, Inc. - Roka Bioscience, Inc. - Thermo Fisher Scientific, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global E.coli Testing Market, by Testing Methods Chapter 5 Global E.coli Testing Market, by End-User Chapter 6 Global E.coli Testing Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/zg...li_testing
ROKA: 0.74 (-0.01), ABT: 38.93 (-0.24), VIVO: 19.61 (-0.03), IDXX: 88.81 (+0.77), DHR: 99.45 (+0.42), ECL: 120.81 (+0.68)
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection
BusinessWire - Tue Oct 14, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, "The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent."
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization
BusinessWire - Mon Sep 29, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape - 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
NanoLogix Announces Publication of a Study in Journal of Microbiology and Experimentation
Marketwired - Tue Jan 05, 5:00AM CST
NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce publication in the Journal of Microbiology and Experimentation of a peer-reviewed study demonstrating dramatically extended shelf life and high-temperature durability of filled petri plates packed in NanoLogix-manufactured gas-charged FlatPacks. The study was performed by one of the world's largest and most prestigious Biomedical Research Centers.
NanoLogix Announces Diagnostic Customization for Major Medical Device Company
Marketwired - Mon Dec 21, 5:00AM CST
NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
E.coli Testing Market (Environmental Testing and Clinical Testing) - Trends and Forecast 2014 - 2022
M2 - Fri Jul 31, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgchcs/e_coli_testing) has announced the addition of the "E.coli Testing Market (Environmental Testing and Clinical Testing) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Microbial testing is one of the important parameters considered for potability of water. This research report on the E.coli testing market explains various advancements in this market and analyzes the global E.coli testing market based on testing method, end-user and geographic regions. This report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments that are included in the report in a precise manner. Environmental E.Coli testing methods are further segmented as membrane filtration, multiple tube fermentation and enzyme substrate methods.Membrane filtration is the most widely used method for bacterial enumeration due its accuracy. However, increasing popularity of P/A tests is expected to alter the trend. The market size and forecast in terms of USD million for each tests has been provided for the period from 2014 to 2022, considering 2012 and 2013 as base years. Apart from revenue analysis, the report also provides volume analysis for each of the segments and sub-segments. The global E.coli testing market report also provides compound annual growth rate (CAGR) for each of the market segment and sub-segment for the forecast period from 2014 to 2022. Companies Mentioned - Abbott Laboratories - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - CPI International, Inc. - Danaher Corporation - EMLab P&K, LLC - Ecolab, Inc. - F.Hoffmann-La Roche Ltd. - IDEXX Laboratories, Inc. - Meridian Bioscience, Inc. - Micrology Laboratories - NanoLogix, Inc. - Nelson Analytical Lab - Pro Lab Diagnostics, Inc. - Roka Bioscience, Inc. - Thermo Fisher Scientific, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global E.coli Testing Market, by Testing Methods Chapter 5 Global E.coli Testing Market, by End-User Chapter 6 Global E.coli Testing Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/zg...li_testing
ROKA: 0.74 (-0.01), ABT: 38.93 (-0.24), VIVO: 19.61 (-0.03), IDXX: 88.81 (+0.77), DHR: 99.45 (+0.42), ECL: 120.81 (+0.68)
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection
BusinessWire - Tue Oct 14, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, "The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent."
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization
BusinessWire - Mon Sep 29, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape - 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
